ArticleMolecular therapy : the journal of the American Society of Gene Therapy2021
Evidence in primates supporting the use of chemogenetics for the treatment of human refractory neuropsychiatric disorders.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Noninvasive focal gene transfer of chemogenetic proteins in the primate brain.Cell reports methods · 2026Article
- Article
- The Future of Chemogenetics for the Treatment of Spasticity.Molecular diagnosis & therapy · 2025Review
- Insights into the Neurobiology of Behavioral Inhibition from Nonhuman Primate Models.Current topics in behavioral neurosciences · 2025Review
- A humanized Gs-coupled DREADD for circuit and behavior modulation.Frontiers in cellular neuroscience · 2025Article
- An Honest Reckoning With the Amygdala and Mental Illness.The American journal of psychiatry · 2024Review
- What can neuroimaging of neuromodulation reveal about the basis of circuit therapies for psychiatry?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Unsupervised decomposition of natural monkey behavior into a sequence of motion motifs.Communications biology · 2024Article
- Imaging-based chemogenetics for dissecting neural circuits in nonhuman primates.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2024Review
- PET reporter systems for the brain.Trends in neurosciences · 2023Review
- Multimodal Imaging for Validation and Optimization of Ion Channel-Based Chemogenetics in Nonhuman Primates.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Review
- Subgenual and Hippocampal Pathways in Amygdala Are Set to Balance Affect and Context Processing.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Real-time trajectory guide tracking for intraoperative MRI-guided neurosurgery.Magnetic resonance in medicine · 2023Article
- Prefrontal influences on the function of the neural circuitry underlying anxious temperament in primates.Oxford open neuroscience · 2023Article
- Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system.Current research in neurobiology · 2023Review
- The use of chemogenetic actuator ligands in nonhuman primate DREADDs-fMRI.Current research in neurobiology · 2023Article
- Efficient viral expression of a chemogenetic receptor in the old-world monkey amygdala.Current research in neurobiology · 2023Article
- DREADD-mediated amygdala activation is sufficient to induce anxiety-like responses in young nonhuman primates.Current research in neurobiology · 2023Article
- Resting-State fMRI-Based Screening of Deschloroclozapine in Rhesus Macaques Predicts Dosage-Dependent Behavioral Effects.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Non-human primate (NHP) models are essential for developing and translating new treatments that target neural circuit dysfunction underlying human psychopathology. As a proof-of-concept for treating neuropsychiatric disorders, we used a NHP model of pathological anxiety to investigate the feasibility of decreasing anxiety by chemogenetically (DREADDs [designer receptors exclusively activated by designer drugs]) reducing amygdala neuronal activity. Intraoperative MRI surgery was used to infect dorsal amygdala neurons with AAV5-hSyn-HA-hM4Di in young rhesus monkeys. In vivo microPET studies with [
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.